Steven L. Hoerter bought $265k of MBX
director at MBX Biosciences, Inc.. 20,000 shares at an average of $13.25, traded Oct 17, 2025, filed Oct 20, 2025.
Score components
- +15RoleDirector
- +13Trade size$265k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context45% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +92.5%, 3m +184.8%, 6m +137.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-243653, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 17, 2025 | POpen-market purchase Common Stockindirect: By Trust | +20,000 | $13.25 | $265k | 20,000 | Oct 20, 2025 |
Related signals
Other insiders at MBX Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | MBX Biosciences, Inc. | Salomon Azoulay Chief Medical Officer | $2.7M 70,003 shares | -100% | |
| 23Weak | MBX Biosciences, Inc. | Salomon Azoulay Chief Medical Officer | $6,824 231 shares | -2% | |
| 33Weak | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $18k 607 shares | -0% | |
| 51Moderate | MBXbuy MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $526k 18,500 shares | +4% | |
| 54Moderate | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $273k 20,000 shares | +4% | |
| 51Moderate | MBXbuy MBX Biosciences, Inc. | Patrick J Heron director, owner | $12M 666,666 shares | +15% | |
| 45Moderate | MBXbuy MBX Biosciences, Inc. | Ora H. Pescovitz director | $45k 7,693 shares | +46% | |
| 51Moderate | MBX Biosciences, Inc. | Carl L Gordon director, owner | $2.0M 190,672 shares | +6% | |
| 54Moderate | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $535k 50,000 shares | +13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.